1A-3 DO VISUAL DECISION AIDS HELP PATIENTS CORRECTLY DIFFERENTIATE BETWEEN A 2% VS A 0.2% RISK?

Monday, October 24, 2016: 2:30 PM
Bayshore Ballroom Salon D, Lobby Level (Westin Bayshore Vancouver)

Raluca Cozmuta, MD, MHS, Emory University, Atlanta, GA, Evan A. Wilhelms, M.S., Vassar College, Poughkeepsie, NY, Valerie Reyna, PhD, Cornell University, Ithaca, NY, Julia Nolte, BSc, Heidelberg University, Heidelberg, Germany and Liana Fraenkel, MD, MPH, Yale University, West Haven, CT

Purpose: Effectively communicating risk information to patients is difficult. We examined whether addition of an icon array (IA), a series of 3 consecutive balance-beam (BB) illustrations depicting how medications regulate the immune system, or both resulted in patients being better able to differentiate between an uncommon (2%) and rare (0.2%) adverse event (AE).

Methods: Patients currently being treated for a chronic inflammatory rheumatic disease were mailed a survey in which they were asked to imagine that their symptoms had recently worsened and that their physician was recommending a new medication. The medication was described using 8 scenarios (manipulated using a 2x4 design). We varied the probability of a serious AE (pneumonia requiring hospitalization): 2% vs 0.2% and the risk presentation format: numbers only, numbers + IA, numbers + BB, and numbers + IA + BB. Route of administration, benefit, and cost were held constant. Each subject responded to a single, randomly-assigned scenario. Dependent variables included perceived riskiness, worry, global gist related to the acceptability of the side effect, and willingness to take the medication (all measured on 5-point ordinal scales).

Results: We mailed 1453 surveys. 465 patients completed and mailed the survey back (32% response rate). Overall, the mean age of responders was 58.99 (SD=14.85); 79.7% of were female; 83.2% White and 39.1% had a low socioeconomic status. There were no statistical differences in demographic or clinical characteristics across the four risk presentation formats. Mean (SD) perceived riskiness, worry, global gist, and willingness to take the medication for 2% versus 0.2% chance of the AE, by socioeconomic status (SES) level, are presented in the Table.

Perceived riskiness was lower for a 0.2% versus 2% risk of the AE in the numbers + IA condition in higher SES subjects. Lower SES subjects who viewed both IA and BB were more worried about the AE and found the AE to be less acceptable in the .2% versus 2% condition.

Conclusion: With the exception of the IA's impact on perceived riskiness, the risk formats used did not enable subjects to correctly differentiate between a 0.2% and a 2% risk of a serious AE.